Tag: johnson
-
J&J questions fairness of hip implant trial, $1 billion verdict
Although legal experts think J&J faces an uphill battle, both they and investors believe the Texas jury's penalty, the largest product liability verdict so far this year, is unlikely to stand. In the two-month trial, five separate people from California argued that design flaws in the metal-on-metal implant made by J&J subsidiary DePuy Orthopaedics caused…
-
J&J questions fairness of hip implant trial, $1 billion verdict
Although legal experts think J&J faces an uphill battle, both they and investors believe the Texas jury's penalty, the largest product liability verdict so far this year, is unlikely to stand. In the two-month trial, five separate people from California argued that design flaws in the metal-on-metal implant made by J&J subsidiary DePuy Orthopaedics caused…
-
Johnson & Johnson approaches Actelion about takeover deal
By Paul Arnold and Ludwig Burger ZURICH/FRANKFURT (Reuters) – U.S. healthcare company Johnson & Johnson said on Friday it was in preliminary talks with Actelion about a potential takeover of Europe's largest biotech firm, currently valued at about $20 billion. Lung disease specialist Actelion confirmed it had been approached and said there was no certainty…
-
J&J makes takeover approach for Swiss drugmaker Actelion: Bloomberg
(Reuters) – U.S. healthcare company Johnson & Johnson has approached Swiss biotechnology firm Actelion Ltd about a potential takeover, Bloomberg reported on Thursday, citing people it said were familiar with the matter. The report said deliberations were still at an early stage following Johnson & Johnson's (J&J) initial offer, and Actelion was working with an…
-
J&J arthritis drug goes up against Humira, with mixed results
(Reuters) – Johnson & Johnson said its experimental sirukumab treatment for rheumatoid arthritis showed mixed results against AbbVie Inc's top-selling Humira in a large trial. By one measure, patients with moderate to severe disease who took sirukumab showed significantly greater improvement in the Phase III study than those taking Humira, J&J said on Saturday. In…
-
After $195 million in talc verdicts, J&J strives to change court
After a $67.5 million jury verdict against Johnson & Johnson on Oct. 27 marked its third straight trial defeat in an onslaught of lawsuits claiming its talc-based products cause ovarian cancer, the company is hoping to reverse the trend by having the cases heard in a different court. All three awards, totaling around $195 million,…
-
Does baby powder cause cancer? Another jury says yes.
TRENTON, N.J. (AP) — For the third time, Johnson & Johnson has been hit with a multimillion-dollar jury verdict over whether the talc in its iconic baby powder causes ovarian cancer when applied regularly for feminine hygiene.
-
Morphosys moves closer to getting first antibody drug on market
German biotech Morphosys moved a step closer to getting its first antibody drug onto the market as its licensee, Johnson & Johnson unit Jenssen, reported positive results from a phase 3 study of psoriasis drug guselkumab. Johnson & Johnson said earlier the experimental biotech drug proved more effective at clearing moderate to severe cases of…
-
J&J psoriasis drug tops placebo, Humira in late stage study
(Reuters) – An experimental biotech drug developed by Johnson & Johnson proved more effective at clearing moderate to severe cases of the skin condition plaque psoriasis than a placebo or Abbvie Inc's big-selling Humira, according to data from a late stage study presented on Saturday. More than 73 percent of patients who received guselkumab experienced…